• Agile Therapeutics Inc., of Princeton, N.J., completed the final Phase III trial of AG200-15 and is on track to submit the new drug application (NDA) for the combination hormonal contraceptive patch to the FDA during the first quarter. The patch, in two Phase III trials enrolling more than 2,000 women, demonstrated its ability to deliver a low dose of ethinyl estradiol and a dose of levonorgestrel consistent with the efficacy and safety profiles of low-dose oral contraceptives.